2022
DOI: 10.1159/000522570
|View full text |Cite
|
Sign up to set email alerts
|

Peroneal Electrical Transcutaneous NeuroModulation as a New Treatment for Patients with Overactive Bladder: An Initial Clinical Experience

Abstract: <b><i>Introduction:</i></b> The aim of this study was to determine whether peroneal electrical Transcutaneous NeuroModulation (peroneal eTNM®) using the URIS® neuromodulation system can be used in individuals with refractory overactive bladder (OAB). <b><i>Methods:</i></b> Eighteen female patients with idiopathic OAB who failed previous behavioral and pharmacological therapy were enrolled. Patients were treated with the URIS® neuromodulation system using active e… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 21 publications
0
2
0
Order By: Relevance
“…Fully noninvasive, highly selective nerve stimulation and continuous adjustment of the stimulation parameters during stimulation represent the main advantages of peroneal eTNM compared with the other methods used for peripheral neuromodulation. 3,4…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…Fully noninvasive, highly selective nerve stimulation and continuous adjustment of the stimulation parameters during stimulation represent the main advantages of peroneal eTNM compared with the other methods used for peripheral neuromodulation. 3,4…”
mentioning
confidence: 99%
“…Fully noninvasive, highly selective nerve stimulation and continuous adjustment of the stimulation parameters during stimulation represent the main advantages of peroneal eTNM compared with the other methods used for peripheral neuromodulation. 3,4 The aim of this study was to assess the safety and efficacy of peroneal eTNM using the URIS neuromodulation system in home-based settings in comparison with standard treatment using solifenacin in treatment-na€ ıve OAB patients (Supplementary Video, https://www.jurology.com).…”
mentioning
confidence: 99%